Respiratory Viral Testing
New England Biolabs, Inc. NEBNext RSV Primer Module - 24 reactions
NEBNext RSV Primer Module - 24 reactions
American Research Products Inc Anti HRSV F F0 Ab RSV 001
Anti-HRSV F/Fusion glycoprotein F0 Antibody (RSV-001) Research Grade
IHEALTH LABS INC iHealth Flu A&B/COVID-19/RSV Rapid Test (2 Pack) - OTC
The iHealth Flu A&B/COVID-19/RSV Rapid Test is intended for overthe-counter (OTC) use for the qualitative detection of SARS-CoV-2, influenza A, influenza B, and respiratory syncytial virus (RSV) protein antigens in anterior nasal (nares) swab samples.The test is intended for non-prescription home use by individuals 14 years of age or older testing themselves, or by adults testing individuals 6 months of age or older. It is intended for use in individuals with signs and symptoms of respiratory tract infection within the first six (6) days of symptom onset, when tested at least twice over a three-day period, with a minimum of 48 hours between tests.
American Research Products Inc Anti RSV F F0 32.4K
Anti-RSV F/Fusion glycoprotein F0 (32 4K) Research Grade
American Research Products Inc Anti RSV F F0 RSB1
Anti-RSV F/Fusion glycoprotein F0 (RSB1) Research Grade
MilliporeSigma T DIAGNOSTICS PARAINFLUENZA 4
Life Sciences,Clinical Diagnostics & Infectious Disease,LIGHT DIAGNOSTICS Parainfluenza 4 Antibody IFA Reagent; ~50 tests
Cayman Chemical ANTIBODY VP-14637 1mg
An RSV inhibitor that demonstrates antiviral activity with an EC50 value of 1.4 nM; interferes directly with RSV fusion (EC50 = 5.4 nM), binding to the viral F protein
IHEALTH LABS INC iHealth Flu A&B/COVID-19/RSV Rapid Test (1 Pack) - OTC
The iHealth Flu A&B/COVID-19/RSV Rapid Test is intended for overthe-counter (OTC) use for the qualitative detection of SARS-CoV-2, influenza A, influenza B, and respiratory syncytial virus (RSV) protein antigens in anterior nasal (nares) swab samples. The test is intended for non-prescription home use by individuals 14 years of age or older testing themselves, or by adults testing individuals 6 months of age or older. It is intended for use in individuals with signs and symptoms of respiratory tract infection within the first six (6) days of symptom onset, when tested at least twice over a three-day period, with a minimum of 48 hours between tests.
![Apexbio Technology LLC Fusion glycoprotein (92-106) [Human respiratory syncytial virus] 5mg](https://assets.fishersci.com/TFS-Assets/CCG/product-images/5000096620.png-250.jpg)
Apexbio Technology LLC Fusion glycoprotein (92-106) [Human respiratory syncytial virus] 5mg
Fusion glycoprotein 92-106 Human respiratory syncytial virus is a synthetic peptide fragment derived from the Human respiratory syncytial virus (HRSV) fusion glycoprotein This peptide is commonly utilized as an antigenic reference in immunological research vaccine design and therapeutic antibody development studies Fusion glycoprotein 92-106 Human respiratory syncytial virus is applied primarily for its immunogenic properties in experimental settings Based on these characteristics Fusion glycoprotein 92-106 Human respiratory syncytial virus holds research potential in immunological assays vaccine development and therapeutic antibody screening related to HRSV